HLN heads into its May 8 results carrying a notably lighter short position than it did just two weeks ago.
The defining feature of the pre-earnings setup is the pace of short covering. Short interest roughly halved between April 23 and April 24 — falling from around 23 million shares to 12.5 million — and has barely budged since. At roughly 0.8% of the free float, that is a low-conviction short book by any measure. Borrowing costs reflect the same ease: cost to borrow is running below 1%, down about 13% on the week. Availability is extremely loose at close to 10,000% of short interest, meaning the lending pool is far from stressed. Options traders show no particular directional lean, with the put/call ratio at 0.089 — right in line with its 20-day average and well below the 52-week high of 0.22. Taken together, the positioning picture is almost conspicuously relaxed. The stock itself is off about 7% over the past month to $9.24, having given back gains on both the day and the week.
The bull case for HLN rests on the durability of its consumer health franchise — brands like Sensodyne, Voltaren and Centrum generate predictable cash flows insulated from the macro cycle. The fundamentals support this: estimated EBITDA of around $4.1 billion against revenue of $15.4 billion, with operating cash flow near $2.9 billion, leaves room for the dividend the market has priced in. The dividend score ranks at the 94th percentile versus peers, and DTC ranks similarly high, reflecting how rarely the short book has threatened the stock. Bears, however, will point to the P/E compressing to 16.3x after a month of weakness — the multiple has shed nearly 1.3 points over 30 days — and to an EPS surprise score that ranks only in the 13th percentile, signalling a track record of underwhelming relative to expectations. The two most recent earnings prints both triggered negative reactions: the stock fell about 2.4% and 2.9% respectively after the last two events, extending to a 5.5% five-day loss after the February print.
Institutional ownership is deep and broadly supportive. BlackRock holds 8% of shares, with Dodge & Cox and Vanguard together accounting for a further 11%. Most major holders added modestly in Q1 2026, with Massachusetts Financial Services standing out — it added roughly 18.4 million shares over the quarter. That kind of conviction at scale suggests the base of patient, fundamental holders is not shaken by the recent softness. Insider data is too stale to draw conclusions from.
The May 8 print is therefore less a test of whether Haleon can defend its franchise and more a question of whether organic growth and margin direction can justify a stock that has drifted lower through a period of macro uncertainty — and whether the covering of short positions reflects genuine re-rating or simply lack of conviction on either side.
See the live data behind this article on ORTEX.
Open HLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
